Pharmacological testing is a critical aspect of drug development, providing valuable insights into the efficacy, safety, and mechanism of action of pharmaceutical compounds. It plays an essential role in evaluating potential drug candidates and optimizing therapeutic strategies. BOC Sciences combines cutting-edge technologies and in-depth research expertise to offer a wide array of pharmacological testing services. Our advanced platforms and validated disease models ensure accurate and reproducible results, supporting drug discovery across various therapeutic areas. Through continuous innovation and stringent quality control, BOC Sciences has positioned itself as a trusted partner in pharmacological testing, helping researchers accelerate the development of safe and effective therapies.
Pharmacological testing is a critical component of drug development. However, researchers frequently encounter persistent challenges that impede progress. Establishing reliable animal and disease models is not only time-consuming but also technically demanding, often resulting in poor reproducibility and elevated experimental costs. Many essential pharmacological assays require access to sophisticated instrumentation and specialized expertise, creating high technical barriers for laboratories lacking these resources. Moreover, interpreting complex pharmacological data necessitates interdisciplinary knowledge in bioinformatics, systems biology, and statistical modeling—domains in which many research teams have limited proficiency. Compounding these issues are manpower constraints, particularly in high-throughput screening projects, where tight timelines and limited personnel make it difficult to maintain experimental quality. Additionally, cumbersome internal procedures, including prolonged reviews, intricate workflows, and excessive documentation, further delay project timelines and reduce operational efficiency.
We provide validated animal and cell models covering various disease types for comprehensive pharmacological activity evaluation.
Our platforms support parallel screening of multiple compounds, significantly enhancing research speed and data output quality.
We adhere to rigorous SOPs in every experiment to guarantee precise, repeatable, and dependable pharmacological results.
We deliver complete statistical analyses and visualized reports, helping you extract meaningful insights from complex datasets.
With flexible scheduling and efficient workflows, we meet tight timelines and accelerate your drug development process.
Our team of skilled scientists offers deep expertise in executing complex pharmacological assays across diverse therapeutic areas.
BOC Sciences offers a robust portfolio of pharmacological testing services tailored to support biomedical research, therapeutic development, and functional compound screening. Our state-of-the-art analytical platforms and cross-disciplinary expertise enable the accurate evaluation of compound activity across diverse biological targets and disease models.
We provide kinase activity screening solutions for evaluating the inhibitory potency and selectivity of compounds targeting disease-relevant kinases. Our services include enzyme-based assays, cellular phosphorylation analysis, and structure–activity relationship (SAR) studies, supporting oncology, inflammation, and metabolic disorder drug discovery.
Our antiviral protease screening services focus on identifying and validating inhibitors against key viral proteases (e.g., HIV, HCV). Using fluorescence resonance energy transfer (FRET), ELISA, and high-throughput screening formats, we ensure rapid and reliable assessment of compound efficacy in both biochemical and cellular contexts.
We offer a comprehensive range of in vitro and in vivo testing services for cardiovascular agents, including receptor binding assays, ion channel activity profiling, and cardiac function evaluations in animal models. These services facilitate the preclinical evaluation of antihypertensive, antiarrhythmic, and lipid-lowering compounds.
Our immunopharmacological assays assess the efficacy of immunosuppressive compounds by measuring cytokine modulation, T cell proliferation, and antigen-presenting cell activity. These studies are essential for the development of therapies in autoimmune diseases, transplantation medicine, and chronic inflammation.
BOC Sciences provides specialized testing services for fatty acid synthase (FASN) inhibitors, evaluating their impact on lipid metabolism, tumor cell viability, and metabolic reprogramming. We combine enzymatic assays with lipidomics and cell-based models to deliver mechanistic insights and efficacy validation.
BOC Sciences offers customized pharmacological testing services, designing and implementing personalized experimental plans based on the specific needs of our clients. By combining advanced technological platforms and a wide range of disease models, we support customized testing in various areas, including drug efficacy, toxicity, and mechanisms. Whether during preclinical research or drug screening, we provide professional technical support to ensure the accuracy and efficiency of each test. BOC Sciences is dedicated to providing tailored solutions for our clients, advancing the smooth progress of drug development.
BOC Sciences has established a comprehensive in vitro and in vivo pharmacological model platform, covering a wide range of classic cell lines, organoids, and disease animal models. With standardized systems and professional techniques, we support full-process research from mechanism studies to efficacy evaluation, ensuring reliable and efficient support for drug development.
| Model Type | Representative Examples |
| Tumor Cells | Lung cancer, breast cancer, liver cancer, colorectal cancer, prostate cancer |
| Stem Cells | Embryonic stem cells, pluripotent stem cells, mesenchymal stem cells |
| Neural Cells | Neurodegenerative disease models, neurotoxicity, neurodevelopment |
| Cardiomyocytes | Cardiotoxicity screening, myocardial function studies |
| Hepatocytes | Drug metabolism, hepatotoxicity, liver disease modeling |
| Pulmonary Epithelial Cells | Respiratory toxicity, airway inflammation, pulmonary disease research |
| Immune Cells | Immunomodulation, inflammation response, immune activation studies |
| Model Type | Representative Examples |
| Tumor Models | Solid tumors, metastasis, drug efficacy, PDX evaluation |
| Inflammatory Models | Colitis, arthritis, systemic inflammation, cytokine response |
| Diabetes Models | Type I/II diabetes, insulin resistance, glucose metabolism |
| Obesity & Metabolic Models | Obesity, lipid metabolism, metabolic syndrome |
| Neurodegenerative Models | Alzheimer’s disease, Parkinson’s disease, cognitive decline |
| Immunological Models | Immunosuppression, autoimmunity, immune activation |
| Liver Injury Models | Acute/chronic liver damage, hepatotoxicity, liver fibrosis |
| Cardiovascular Models | Myocardial infarction, hypertension, heart failure |
BOC Sciences' pharmacological testing technology platform is equipped with advanced instruments, dedicated to providing comprehensive pharmacological evaluation, toxicity screening, and mechanism research services. The platform includes a variety of high-end instruments, efficiently and accurately supporting various pharmacological studies, ensuring the reliability of experimental results and precision of data, meeting the needs throughout the drug development process.
At BOC Sciences, we offer a comprehensive suite of pharmacological test assays to support your drug discovery and development needs. Our services cover a wide range of assay types, each designed to evaluate the efficacy, toxicity, and mechanism of action of pharmaceutical compounds. Below are some of the key tests we provide:
Our MTT assay provides a reliable method for evaluating cell proliferation and survival by measuring metabolic activity. It is widely used for drug efficacy screening, helping identify promising compounds with therapeutic potential.
The CCK-8 assay offers high sensitivity for assessing cell proliferation and cytotoxicity. This test is frequently employed in drug efficacy evaluations, providing accurate insights into cell viability and the effectiveness of therapeutic agents.
Our Caspase-3 activity assay measures the enzymatic activity of Caspase-3, a critical mediator of apoptosis. This assay is used to assess the extent of cell death and evaluate the pro-apoptotic effects of drug candidates.
The LDH assay is designed to assess cell membrane integrity by measuring lactate dehydrogenase (LDH) release. It is a key test for determining cytotoxicity, enabling precise evaluations of drug-induced cell damage.
We offer Western blotting services to analyze protein expression and phosphorylation status. This technique evaluates the activation of cellular signaling pathways, providing detailed information on the molecular mechanisms underlying drug actions.
Our ELISA services allow the quantification of cytokines or other biomarkers, which are crucial for immunology and inflammatory response studies. This sensitive method is widely used in assessing immune responses and therapeutic effects in drug development.
Using flow cytometry, we evaluate cell surface markers, cell cycle distribution, and apoptosis in a high-throughput manner. This technique is instrumental in profiling cell populations and assessing drug effects on cellular functions.
Our protease inhibition assay evaluates the efficacy of antiviral drugs by assessing their ability to inhibit viral proteases. This key test helps determine the antiviral potential and mechanism of action of drug candidates.
The Troponin I assay is used to detect cardiac injury markers, providing valuable data for cardiovascular drug testing. It is particularly relevant for evaluating the safety and efficacy of drugs targeting heart-related conditions.
We offer Treg differentiation assays to examine the impact of immunosuppressive agents on T regulatory cell differentiation. This assay is vital for assessing immunomodulatory treatments in autoimmune disorders and transplant therapy.
Our Annexin V assay detects early apoptotic cells through Annexin V binding. This crucial test provides insights into drug-induced apoptosis, allowing for better understanding of drug safety and mechanisms of cell death.
Engage with the client to thoroughly understand their pharmacological research objectives, compound characteristics, and intended therapeutic areas (e.g., oncology, dermatology, neurology). This ensures the testing strategy aligns with specific biological targets, compound classes, and mechanistic hypotheses.
Design a customized experimental plan, selecting suitable in vitro or in vivo assay systems (e.g., receptor binding assays, enzyme inhibition tests, cell-based functional assays), and determine appropriate dose ranges, endpoints, and controls for precise efficacy evaluation.
Establish and validate relevant experimental systems, including engineered cell lines, primary cells, or animal models. Incorporate validated biomarkers or readout technologies (e.g., reporter gene assays, flow cytometry, ELISA, qPCR) to ensure reproducibility and biological relevance.
Perform systematic pharmacological testing under optimized conditions, including dose–response studies, EC50/IC50 determination, time-course analysis, and functional profiling to characterize the potency, efficacy, and mode of action of test compounds.
Collect quantitative data from all assay systems and conduct statistical analyses to assess pharmacodynamic behavior, structure–activity relationships (SAR), and off-target interactions. Utilize bioinformatics tools where needed for multidimensional data integration.
Provide a comprehensive and data-driven report that includes dose-response curves, efficacy metrics (e.g., IC50, Emax), mechanistic insights, assay methodology, and recommendations for further optimization. Reports are tailored for decision-making in early drug discovery or preclinical validation.
A pharmacological test assesses how a compound influences biological systems at the molecular, cellular, or organism level. It helps explore therapeutic effects, mechanisms of action, and potential toxicity, supporting scientific understanding and early-stage evaluation in drug discovery and biomedical research.
Pharmacological testing reveals how compounds affect biological targets, ensuring they perform as intended while minimizing unwanted effects. It provides critical data for evaluating therapeutic potential, guiding compound optimization, and understanding biological pathways in various research contexts.
Common types include receptor binding assays, enzyme inhibition studies, cell viability and apoptosis assays, and in vivo disease models. These tests cover diverse biological systems and are tailored to analyze efficacy, mechanism, selectivity, and safety in experimental research.
These tests help identify and validate active compounds, refine their biological profiles, and determine optimal dosages. They also support the exploration of mechanisms and guide the selection of candidates for further biological studies, playing a key role in early drug research.
